|Year : 2018 | Volume
| Issue : 10 | Page : 1254-1259
The accuracy of risk malignancy index in prediction of malignancy in women with adnexal mass in Basrah, Iraq
JN Al-Asadi1, SK Al-Maliki1, F Al-Dahhhan2, L Al-Naama2, F Suood3
1 Department of Community Medicine, College of Medicine, Basrah University, Basrah, Iraq
2 Department of Biochemistry, College of Medicine, Basrah University, Basrah, Iraq
3 Basrah General Health Directorate, Basrah, Iraq
|Date of Acceptance||23-Aug-2017|
|Date of Web Publication||8-Oct-2018|
Dr. S K Al-Maliki
College of Medicine, Basrah University, Basrah
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Background: Adnexal masses indicate a variety of gynecological and nongynecological disorders, which may be benign or malignant. Early detection of malignancy is crucial to a proper planning of treatment and improvement of survival. Objective: To determine the accuracy of risk of malignancy index (RMI) in prediction of malignant adnexal mass. Subjects and Methods: This was a prospective multicenter study which included 101 women with adnexal masses. RMI2 with cutoff value of 200 was used to discriminate between benign and malignant tumors. Histopathological examination was used to confirm the final diagnosis. Results: Out of the studied women, 20.8% proved to have malignant tumors. The RMI showed a sensitivity of 100%, a specificity of 96.2%, a positive predictive value of 87.5%, and a negative predictive value (NPV) of 100%. The RMI identified malignant cases more accurately than any individual criterion in diagnosing ovarian cancer. The receiver operating characteristic analysis showed that the area under the curve of the RMI, CA 125, ultrasound, and menopausal status were significantly high with values of 1.0, 0.99, 0.86, and 0.85, respectively. Conclusion: The RMI is a simple sensitive, practical, and reliable tool in preoperative discrimination between benign and malignant adnexal masses that can facilitate selection of cases for timely referral to oncology center.
Keywords: Accuracy, adnexal masses, Basrah, malignancy, prediction
|How to cite this article:|
Al-Asadi J N, Al-Maliki S K, Al-Dahhhan F, Al-Naama L, Suood F. The accuracy of risk malignancy index in prediction of malignancy in women with adnexal mass in Basrah, Iraq. Niger J Clin Pract 2018;21:1254-9
|How to cite this URL:|
Al-Asadi J N, Al-Maliki S K, Al-Dahhhan F, Al-Naama L, Suood F. The accuracy of risk malignancy index in prediction of malignancy in women with adnexal mass in Basrah, Iraq. Niger J Clin Pract [serial online] 2018 [cited 2020 Jul 12];21:1254-9. Available from: http://www.njcponline.com/text.asp?2018/21/10/1254/242847
| Introduction|| |
Adnexal masses indicate a variety of disorders from gynecologic and nongynecologic causes; they may be benign or malignant. The initial detection and evaluation of an adnexal mass necessitate a thorough history, physical examination, and timely appropriate laboratory and radiographic investigations.,
The goal of evaluation of adnexal masses is to differentiate between benign or malignant conditions such as ovarian cancer. This is because early stage diagnosis leads to better planning of treatment and more acceptable prognosis.,,,,
Ovarian malignancy is the principal cause of death from gynecologic malignancy worldwide.,
No one modality was sufficient to predict accurately the presence of an ovarian malignancy. Therefore, Jacobs et al. established the risk of malignancy index (RMI) which is called later RMI 1, calculated as the product of ultrasound, CA-125 (biochemical data), and menopausal status (demographic characteristic), for referral of patients with adnexal mass to gynecologic oncology centers. The RMI 1 was modified by Tingulstad et al. in 1996 (RMI 2) and again in 1999 (RMI 3). The three versions of the RMI have been confirmed retrospectively and prospectively in different clinical studies ,, where a cutoff value of 200 revealed the best judgment between benign and malignant pelvic masses, with high sensitivity and specificity levels (sensitivity 51%–90% and specificity 51%–97%). RMI 4 was presented by Yamamoto et al. The main difference between RMI 1 and the other versions is that RMI 1 scores ultrasound finding as 0 when none of the ultrasound features were present whereas the other versions score absence of ultrasound features as 1.
The chief benefit of the four RMIs is that an unsophisticated scoring method can be pertained straightforwardly into practice for daily use without the insertion of costly or complicated procedures (such as computed tomography scan and magnetic resonance imaging). It can be useful in low-resource locations.
The aim of this study was to find if the multiparametric RMI score could be used as useful tool to differentiate between benign and malignant tumors in women with adnexal masses. The prospective confirmation of the RMI is the leading step for the longstanding purpose of this study, which is to apply a risk scoring system in Basrah.
| Subjects and Methods|| |
The study was a prospective observational multicenter one done during January 2015–October 2015 at three major hospitals in Basrah (Basrah Maternity Hospital, Al-Mawnea Hospital, and Al-Fayhaa Hospital). Data were collected using a questionnaire form inquiring about information regarding women age and menopausal status. All women with adnexal masses, consecutively referred to the aforementioned hospitals for laparotomy during the study period, were included. The total number was 101 women, which represents the sample size. Pregnant women and known cases of ovarian cancers were excluded. The aim of the study was explained appropriately, and informed written consent was obtained from each patient before enrollment in the study.
A 2D ultrasound was performed transabdominally with a full bladder by specialized radiologists in these hospitals. Score was assigned for the following ultrasound features suggestive of malignancy: the presence of a multilocular cystic lesion, solid areas, bilateral lesions, ascites, and intra-abdominal metastases, scored as one point for each. A total ultrasound score (US) was thus calculated for each patient. Postmenopausal status was defined as ≥1 year of amenorrhea or age older than 50 years in women who had undergone hysterectomy.
Serum samples were collected preoperatively, and serum CA-125 levels were measured using fluorescence enzyme immunoassay (Automated immunoassay analyzer AIA-360, Tosoh Bioscience, Japan) in accordance with the manufacturer's instructions.
RMI 2 was used because it was found to be reliable in differentiation between benign and malignant disease by many investigators.,, It is the product of M, CA-125, and US where M is the menopausal status, US is the ultrasound finding, and CA-125 is the serum level of CA-125.
The following five ultrasound features were sought and each one was given 1 point if present: bilaterality, multilocularity, solid areas, extraovarian tumors (evidence of metastases), and ascites. If the total of these points was 0 or 1; an ultrasound score of US = 1, whereas if the total of the points was 2 or more; a score of US = 4. For premenopausal women; M = 1, and for postmenopausal women; M = 4. The serum level of CA-125 was applied directly to the calculation.
A cutoff value of 200 for RMI was used in this study because it was considered by many studies as the best discrimination value between benign and malignant pelvic masses due to its high sensitivity and specificity levels.,,, The histopathological diagnosis was considered as the gold standard for definite outcome.
The Ethical Committees of College of Medicine, University of Basrah, and Barah General Health Directorate approved the study.
Statistical software SPSS (IBM Corp., Chicago, Illinois, USA) v. 20 was used for data input and analysis. Quantitative variables presented as means with standard deviations. Discrete variables were presented as numbers and percentages. Chi-square test was used to test the significance of association between discrete variables. The difference in means of normally distributed variables between 2 groups was assessed by t-test. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of RMI were determined. Sensitivity was calculated as the proportion of true positives out of true positives + false negatives, specificity was calculated as the proportion of true negatives out of true negatives + false positives, PPV was calculated as the proportion of true positives out of true positives + false positives, and NPV was calculated as the proportion of true negatives out of true negatives + false negative. For all statistical analyses, P < 0.05 was considered statistically significant.
| Results|| |
A total of 101 patients were enrolled in this study. According to the histopathological examination of the specimens, 21 (20.8%) were malignant and 80 (79.2%) were benign. The mean age of patients was 41.4 ± 13.5 years (36.9 ± 10.7 for patients with benign tumors and 58.4 ± 8.4 for patients with malignant tumors, P < 0.001).
As shown in [Table 1], highly significant differences were found between patients with benign and malignant tumors regarding all studied basic characteristics.
|Table 1: Comparison of basic characteristics of women with benign and malignant adnexal masses|
Click here to view
The RMI showed higher sensitivity and specificity than its components separately [Table 2].
|Table 2: The sensitivity, specificity, positive predictive value, and negative predictive value of the risk of malignancy index and other studied parameters|
Click here to view
As shown in [Table 3], more than half of the cancers (52.4%) were either mucinous adenocarcinoma or serous adenocarcinoma. In addition, most of them were in advanced stage.
|Table 3: The distribution of histopathological diagnosis and staging of cancers|
Click here to view
[Table 4] shows the histopathological distribution of benign tumors. Dermoid cysts represent 28.8% of these tumors. While Corpus luteum and simple cysts constituted 26.2% and 20.0% of all benign tumors, respectively.
The receiver operating characteristic analysis of the RMI, CA-125, ultrasound, and menopausal status showed that the values of area under the curve were significantly high with a value of 1.00, 0.99, 0.86, and 0.85, respectively (P < 0.001) [Figure 1].
|Figure 1: Receiver operator curve showing the performance of risk of malignancy index, CA-125, ultrasound score, and menopausal status|
Click here to view
| Discussion|| |
Adnexal mass is one of the most frequent reasons for women to be referred to gynecological oncologist. The rate of malignancy of pelvic masses is about 24% in premenopausal women, and it increases to ≥60% in postmenopausal women. In our study, 20.8% of the adnexal masses showed malignancy on histopathological examination (76.2% of them were in postmenopausal women). The results seem to agree with earlier reports of similar incidence rates and predominance in postmenopausal patients. The mean age of the patients with adnexal masses in our study was 41.4 ± 13.5 years (36.9 ± 10.7 years for women with benign tumors and 58.4 ± 8.4 years for those with malignant tumors). The occurrence of ovarian cancer was reported to be rare before age of 40 years, but it increases steadily thereafter, and it reaches its peak at the age of 50–60 years.
Our study showed that RMI 2 was reliable in preoperative discrimination between malignant and benign adnexal masses at cutoff value of 200. It yielded sensitivity and specificity of 100% and 96.2%, respectively, which were higher than that reported by other studies. Obeidat et al. reported a sensitivity of 90% and specificity of 89%, while Håkansson et al. reported sensitivity and specificity of 92% and 82%, respectively. During 2010, van den Akker et al. reported sensitivity and specificity of 81% and 85%, respectively.
This study also revealed the superiority of RMI in detection of malignancy over the individual parameters; a result which had been found by others.
The RMI is particularly sensitive to elevations of serum CA 125. Elevated levels of CA 125 were found in >90% of patients with advanced stage ovarian cancer but in only 50% of patients with Stage I disease. Borderline malignancies that occur in younger women and mucinous cancers manage to have lower RMI scores compared to invasive malignancies and are consequently less detectable. The different characters, they exhibit, can clarify this. Therefore, they have low scores on both ultrasound and CA 125 levels., While in this study, the late presentation of the patients with adnexal masses and after confirmation with histopathology, most of the malignancies showed stages two or more in which the RMI showed high scores of ultrasound and very high levels of CA 125. Hence, this may explain the high readings of RMI in our study.
A significant difference in serum level of CA 125 between patients with malignant and benign tumors was found in this study, a result that is similar to that reported by others,, with a sensitivity of 100% and specificity of 80% which are similar to that found in other studies.,
The specificity of CA 125 is expected to be lower in premenopausal patients. CA 125 levels fluctuate during the menstrual cycle, being the highest during menstruation. In addition, diseases such as endometriosis and pelvic inflammatory disease are more frequent in premenopausal women. These diseases are known to cause elevated CA 125 values., In our study, 76.2% of the malignant tumors were in postmenopausal women, and about one-fourth (23.8%) of them were in premenopausal women.
Ultrasonography is universally regarded as good imaging technique for diagnosis of ovarian mass. In our study, an US of 4 had a sensitivity of 95.2% and NPV of 98.3% in prediction of malignancy. This result is higher than the sensitivity and NPVs reported by Aziz and Najmi  (78.3% and 96.1%, respectively), but Arun-Muthuvel and Jaya  reported higher sensitivity and specificity than our study (96.1% and 81%, respectively).
Although RMI seems to be a reliable method in discrimination between malignant and benign pelvic masses,,, its utilization in the community depends on the inclination of clinicians to its usage and whether a considerable proportion of patients with suspected ovarian cancer will be referred to a gynecologic oncologist with appropriate expertise. To maximize its use, access of information for women and educational programs for health professionals are required.
Some researchers reported that RMI is inadequate in detecting ovarian cancers in a population where nonepithelial ovarian cancer and borderline ovarian tumors are prevalent., However, they suggest further validation of their results.
Some of the important advantages of RMI are its relative simplicity and applicability in assessment of patients with pelvic masses in nonspecialized gynecological units., In addition to its potential role in discrimination between benign and malignant tumors, RMI provides a rational basis for referral of women with malignancy for effective surgical intervention.,
This study could be criticized for its small sample size including high proportion of patients with late stage cancer. Nevertheless, the results of our study are in line with that previously established, which suggest that the RMI is a valuable tool and the method of choice for discrimination between malignant and benign adnexal masses particularly in developing countries.,,
| Conclusion|| |
Based on our results, we conclude that, in the absence of a definitive biomarker, the multipara metric risk of malignancy index should be reliable tool for assessment of a patient with adnexal mass before operation, and a cutoff point of 200 shows a very high sensitivity, specificity, positive, and NPVs for discriminating malignant and benign adnexal masses.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Givens V, Mitchell GE, Harraway-Smith C, Reddy A, Maness DL. Diagnosis and management of adnexal masses. Am Fam Physician 2009;80:815-20.
Royal College of Obstetricians and Gynecologists. Management of Suspected Ovarian Masses in Premenopausal Women. Green–Top Guideline No. 62; November, 2011.
Aziz AB, Najmi N. Is risk malignancy index a useful tool for predicting malignant ovarian masses in developing countries? Obstet Gynecol Int 2015;2015:951256.
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 2002;20:1248-59.
Young RC, Decker DG, Wharton JT, Piver MS, Sindelar WF, Edwards BK, et al.
Staging laparotomy in early ovarian cancer. JAMA 1983;250:3072-6.
Gillis CR, Hole DJ, Still RM, Davis J, Kaye SB. Medical audit, cancer registration, and survival in ovarian cancer. Lancet 1991;337:611-2.
Engelen MJ, Kos HE, Willemse PH, Aalders JG, de Vries EG, Schaapveld M, et al.
Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer 2006;106:589-98.
Bouzari Z, Yazdani S, Ahmadi MH, Barat S, Kelagar ZS, Kutenaie MJ, et al.
Comparison of three malignancy risk indices and CA-125 in the preoperative evaluation of patients with pelvic masses. BMC Res Notes 2011;4:206.
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG, et al.
Arisk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990;97:922-9.
Tingulstad S, Hagen B, Skjeldestad FE, Onsrud M, Kiserud T, Halvorsen T, et al.
Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. Br J Obstet Gynaecol 1996;103:826-31.
Tingulstad S, Hagen B, Skjeldestad FE, Halvorsen T, Nustad K, Onsrud M, et al.
The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals. Obstet Gynecol 1999;93:448-52.
Obeidat BR, Amarin ZO, Latimer JA, Crawford RA. Risk of malignancy index in the preoperative evaluation of pelvic masses. Int J Gynaecol Obstet 2004;85:255-8.
Bailey J, Tailor A, Naik R, Lopes A, Godfrey K, Hatem HM, et al.
Risk of malignancy index for referral of ovarian cancer cases to a tertiary center: Does it identify the correct cases? Int J Gynecol Cancer 2006;16 Suppl 1:30-4.
Ulusoy S, Akbayir O, Numanoglu C, Ulusoy N, Odabas E, Gulkilik A, et al.
The risk of malignancy index in discrimination of adnexal masses. Int J Gynaecol Obstet 2007;96:186-91.
Yamamoto Y, Yamada R, Oguri H, Maeda N, Fukaya T. Comparison of four malignancy risk indices in the preoperative evaluation of patients with pelvic masses. Eur J Obstet Gynecol Reprod Biol 2009;144:163-7.
Moore RG, Bast RC Jr. How do you distinguish a malignant pelvic mass from a benign pelvic mass? Imaging, biomarkers, or none of the above. J Clin Oncol 2007;25:4159-61.
Aktürk E, Karaca RE, Alanbay I, Dede M, Karaşahin E, Yenen MC, et al.
Comparison of four malignancy risk indices in the detection of malignant ovarian masses. J Gynecol Oncol 2011;22:177-82.
Morgante G, la Marca A, Ditto A, De Leo V. Comparison of two malignancy risk indices based on serum CA125, ultrasound score and menopausal status in the diagnosis of ovarian masses. Br J Obstet Gynaecol 1999;106:524-7.
Moolthiya W, Yuenyao P. The risk of malignancy index (RMI) in diagnosis of ovarian malignancy. Asian Pac J Cancer Prev 2009;10:865-8.
van den Akker PA, Aalders AL, Snijders MP, Kluivers KB, Samlal RA, Vollebergh JH, et al.
Evaluation of the risk of malignancy index in daily clinical management of adnexal masses. Gynecol Oncol 2010;116:384-8.
Meray O, Türkçüoğlu I, Meydanlı MM, Kafkaslı A. Risk of malignancy index is not sensitive in detecting non-epithelial ovarian cancer and borderline ovarian tumor. J Turk Ger Gynecol Assoc 2010;11:22-6.
Mondal SK, Banyopadhyay R, Nag DR, Roychowdhury S, Mondal PK, Sinha SK, et al.
Histologic pattern, bilaterality and clinical evaluation of 957 ovarian neoplasms: A 10-year study in a tertiary hospital of Eastern India. J Cancer Res Ther 2011;7:433-7.
Håkansson F, Høgdall EV, Nedergaard L, Lundvall L, Engelholm SA, Pedersen AT, et al.
Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with a pelvic mass. Acta Obstet Gynecol Scand 2012;91:496-502.
Davies AP, Jacobs I, Woolas R, Fish A, Oram D. The adnexal mass: Benign or malignant? Evaluation of a risk of malignancy index. Br J Obstet Gynaecol 1993;100:927-31.
Yazbek J, Aslam N, Tailor A, Hillaby K, Raju KS, Jurkovic D, et al.
Acomparative study of the risk of malignancy index and the ovarian crescent sign for the diagnosis of invasive ovarian cancer. Ultrasound Obstet Gynecol 2006;28:320-4.
Nustad K, Bast RC Jr., Brien TJ, Nilsson O, Seguin P, Suresh MR, et al.
Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen:First report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine. Tumour Biol 1996;17:196-219.
Jordan SM, Bristow RE. Ovarian cancer biomarkers as diagnostic triage tests. Curr Biomark Find 2013;3:35-42.
Park JW, Hwang SO, Park JH, Lee BI, Lee JH, Kim KW, et al
. Discrimination between benign and malignant pelvic masses using the risk of malignancy index 1. J Korean Soc Menopause 2013;19:1825.
Strigini FA, Gadducci A, Del Bravo B, Ferdeghini M, Genazzani AR. Differential diagnosis of adnexal masses with transvaginal sonography, color flow imaging, and serum CA 125 assay in pre- and postmenopausal women. Gynecol Oncol 1996;61:68-72.
Arun-Muthuvel V, Jaya V. Pre-operative evaluation of ovarian tumors by risk of malignancy index, CA125 and ultrasound. Asian Pac J Cancer Prev 2014;15:2929-32.
Clarke SE, Grimshaw R, Rittenberg P, Kieser K, Bentley J. Risk of malignancy index in the evaluation of patients with adnexal masses. J Obstet Gynaecol Can 2009;31:440-5.
Karimi-Zarchi M, Mojaver SP, Rouhi M, Hekmatimoghaddam SH, Moghaddam RN, Yazdian-Anari P, et al.
Diagnostic value of the risk of malignancy index (RMI) for detection of pelvic malignancies compared with pathology. Electron Physician 2015;7:1505-10.
Yörük P, Dündar O, Yildizhan B, Tütüncü L, Pekin T. Comparison of the risk of malignancy index and self-constructed logistic regression models in preoperative evaluation of adnexal masses. J Ultrasound Med 2008;27:1469-77.
Campos C, Sarian LO, Jales RM, Hartman C, Araújo KG, Pitta D, et al.
Performance of the risk of malignancy index for discriminating malignant tumors in women with adnexal masses. J Ultrasound Med 2016;35:143-52.
[Table 1], [Table 2], [Table 3], [Table 4]